aibio
Listings ·
Matinas Biopharma effects one-for-fifteen reverse stock split
The reverse split of Matinas BioPharma Holdings took effect at 12:01 a.m. Eastern Time on September 28, 2026. Every 15 shares of common stock became one share.
MTNB Matinas Biopharma Holdings, Inc.
Matinas Biopharma Holdings (MTNB) news MTNB reverse split, offering and Nasdaq notice news
Latest Matinas Biopharma Holdings news
- Listings
Matinas BioPharma sets one-for-fifteen reverse stock split
The board approved a one-for-fifteen reverse split of the common stock, effective 12:01 a.m. Eastern Time on September 28, 2026, under the existing MTNB symbol.
- Listings
Matinas BioPharma receives NYSE American stockholders' equity notice
The exchange says stockholders' equity was $1.8 million at June 30, 2026, below the $2.0 million standard, and the listing continues under an accepted plan through October 2, 2027.
- Financings
BTIG terminates Matinas at-the-market sales agreement
BTIG, LLC ended the 2020 at-the-market sales agreement with Matinas BioPharma, effective July 23, 2026, and the company says it owes no termination penalties.
- Mergers
Matinas plans GH Power combination and sells MAT2203 to Azurity
Matinas BioPharma agreed to combine with GH Power in a business combination expected to close in the fourth quarter of 2026, and to sell its MAT2203 and LNC business to Azurity Pharmaceuticals for $4.0 million upfront.
- Listings
Matinas BioPharma receives NYSE American equity notice, plan accepted
NYSE American says Matinas BioPharma fell short of two stockholders' equity standards and accepted its compliance plan, with a plan period through October 2, 2027.
- Listings
Matinas BioPharma receives NYSE American notice on three equity standards
NYSE American says Matinas BioPharma is out of compliance with three stockholders' equity standards, with equity of $4.83 million at December 31, 2025, and a plan due by May 2, 2026.
- Distress
Matinas BioPharma files NT 10-K, says it needs more time to complete 2024 annual report
Matinas said it needs more time to review its financial statements for the year ended December 31, 2024 and plans to file its Form 10-K within the fifteen calendar day extension. It does not anticipate a significant change in results of operations.
- Distress
Matinas BioPharma delays annual report for year ended December 31, 2024
The company needs more time to complete the review of its financial statements and plans to file within the fifteen calendar day extension.
- Listings
Matinas BioPharma gets NYSE American deficiency notice for missing 2024 annual meeting
The January 6, 2025 letter cites Section 704 of the NYSE American Company Guide. The shares stay listed with a ".BC" indicator, and Matinas says it will hold its annual meeting no later than December 31, 2025.
What Matinas Biopharma Holdings does
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on therapies built on its lipid nanocrystal (LNC) platform. Its lead product candidate, MAT2203, is an oral form of amphotericin B, a highly potent antifungal drug that the company says has been made oral, safe and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. After the EnACT Phase 2 trial in cryptococcal meningitis, MAT2203 was positioned for a single Phase 3 registration trial, the ORALTO trial, in support of a New Drug Application for invasive aspergillosis in patients with limited treatment options. Following an 80% reduction in workforce, the company paused further clinical development of MAT2203 and continues to seek one or more development or commercialization partners. The company says it will require either a partnership transaction or additional capital before commencing the ORALTO trial. It keeps the MAT2203 Investigational New Drug application active with the FDA, maintains an Expanded/Compassionate Use Access Program, and maintains its obligations under a license agreement with Rutgers University. It has also paused internal development of LNC programs in oncology and inflammatory diseases while it evaluates strategic alternatives for them.
| Product or program | What it is | Stage |
|---|---|---|
| MAT2203 | Oral amphotericin B antifungal for invasive fungal infections | Phase 2 completed; ORALTO Phase 3 awaits partnership or capital |
| LNC platform | Lipid nanocrystal delivery technology for small molecules and oligonucleotides | Internal pipeline paused |
Matinas Biopharma Holdings annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $85,000 | $11.4 million |
| Net income (loss) | -$10.3 million | -$24.3 million |
| Cash from operations | -$7.0 million | -$15.9 million |
| Cash and equivalents | $4.0 million | $7.3 million |
Questions about Matinas Biopharma Holdings
Did Matinas Biopharma Holdings do a reverse stock split?
Our latest story on this, dated Sep 25, 2026: "Matinas Biopharma effects one-for-fifteen reverse stock split". The story links the filing or release it is based on. Read the story.
Has Matinas Biopharma Holdings raised money recently?
Our latest story on this, dated Jul 24, 2026: "BTIG terminates Matinas at-the-market sales agreement". The story links the filing or release it is based on. Read the story.
Has Matinas Biopharma Holdings received a Nasdaq deficiency notice?
Our latest story on this, dated Jan 10, 2025: "Matinas BioPharma gets NYSE American deficiency notice for missing 2024 annual meeting". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Matinas Biopharma Holdings?
Matinas Biopharma Holdings, Inc. trades under the ticker MTNB on AMEX.
Where is Matinas Biopharma Holdings listed?
Matinas Biopharma Holdings, Inc. is listed on AMEX.
What is the SEC CIK of Matinas Biopharma Holdings?
The SEC Central Index Key (CIK) for Matinas Biopharma Holdings, Inc. is 1582554. Its filings are on SEC EDGAR.
How many shares does Matinas Biopharma Holdings have outstanding?
14,692,796 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-13.
Which country or territory is Matinas Biopharma Holdings listed under?
Our directory records Matinas Biopharma Holdings, Inc. under United States.
What does Matinas Biopharma Holdings do?
Our directory classifies Matinas Biopharma Holdings, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Matinas Biopharma Holdings?
The ISIN recorded for Matinas Biopharma Holdings, Inc. is US5768104029.
Does aibio.space cover Matinas Biopharma Holdings?
aibio.space lists Matinas Biopharma Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Matinas Biopharma Holdings incorporated?
SEC records list its state or country of incorporation as DE.
What does Matinas Biopharma Holdings develop?
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on therapies built on its lipid nanocrystal (LNC) platform. Its lead product candidate, MAT2203, is an oral form of amphotericin B, a highly potent antifungal drug that the company says has been made oral, safe and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections.
What is MAT2203 from Matinas Biopharma Holdings?
MAT2203: Oral amphotericin B antifungal for invasive fungal infections Stage: Phase 2 completed; ORALTO Phase 3 awaits partnership or capital.
What is LNC platform from Matinas Biopharma Holdings?
LNC platform: Lipid nanocrystal delivery technology for small molecules and oligonucleotides Stage: Internal pipeline paused.
Investor discussion: Matinas Biopharma Holdings
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 8.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
- Distress
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
- Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,3.03,5.01,5.02,5.03,7.01,8.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
- Distress
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,2.06,5.02,7.01,8.01,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- Matinas BioPharma Holdings, Inc.
- CIK
- 1582554
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- MTNB (NYSE)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ, 07921
- Phone
- 908-484-8805
- Shares outstanding
- 14,692,796 as of 2026-08-10 (10-Q filed 2026-08-13)
Recent filings
Listing details
- Company
- Matinas Biopharma Holdings, Inc.
- Ticker
- MTNB
- Listing
- AMEX
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US5768104029
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction